{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:54:35Z","timestamp":1776268475371,"version":"3.50.1"},"reference-count":292,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER) funds","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER) funds","award":["PRR-09\/C06-I07\/2024.P11721"],"award-info":[{"award-number":["PRR-09\/C06-I07\/2024.P11721"]}]},{"name":"Portuguese funds","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Portuguese funds","award":["PRR-09\/C06-I07\/2024.P11721"],"award-info":[{"award-number":["PRR-09\/C06-I07\/2024.P11721"]}]},{"name":"CHAIR in Onco-Innovation from Faculty of Medicine, University of Porto (FMUP)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"CHAIR in Onco-Innovation from Faculty of Medicine, University of Porto (FMUP)","award":["PRR-09\/C06-I07\/2024.P11721"],"award-info":[{"award-number":["PRR-09\/C06-I07\/2024.P11721"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The characterization of a drug\u2019s ADME (absorption, distribution, metabolism, and excretion) profile is crucial for accurately determining its safety and efficacy. The rising prevalence of polypharmacy has significantly increased the risk of drug-drug interactions (DDIs). These interactions can lead to altered drug exposure, potentially compromising efficacy or increasing the risk of adverse drug reactions (ADRs), thereby posing significant clinical and regulatory concerns. Traditional methods for assessing potential DDIs rely heavily on in vitro models, including enzymatic assays and transporter studies. While indispensable, these approaches have inherent limitations in scalability, cost, and ability to predict complex interactions. Recent advancements in analytical technologies, particularly the development of more sophisticated cellular models and computational modeling, have paved the way for more accurate and efficient DDI assessments. Emerging methodologies, such as organoids, physiologically based pharmacokinetic (PBPK) modeling, and artificial intelligence (AI), demonstrate significant potential in this field. A powerful and increasingly adopted approach is the integration of in vitro data with in silico modeling, which can lead to better in vitro-in vivo extrapolation (IVIVE). This review provides a comprehensive overview of both conventional and novel strategies for DDI predictions, highlighting their strengths and limitations. Equipping researchers with a structured framework for selecting optimal methodologies improves safety and efficacy evaluation and regulatory decision-making and deepens the understanding of DDIs.<\/jats:p>","DOI":"10.3390\/pharmaceutics17060747","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:11:08Z","timestamp":1749190268000},"page":"747","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4957","authenticated-orcid":false,"given":"Lara","family":"Marques","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"ref_1","unstructured":"Food and Drug Administration (1987). Guideline for the Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application."},{"key":"ref_2","unstructured":"European Medicines Agency (2007). Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/138920008783331086","article-title":"Cell Lines: A Tool for In Vitro Drug Metabolism Studies","volume":"9","author":"Donato","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2174\/1568026033452096","article-title":"The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery","volume":"3","author":"Lin","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425255.2.2.183","article-title":"Hepatocyte Cell Lines: Their Use, Scope and Limitations in Drug Metabolism Studies","volume":"2","author":"Castell","year":"2006","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/tx500444e","article-title":"Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals","volume":"28","author":"Rendic","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Patel, R., Barker, J., and Elshaer, A. (2020). Pharmaceutical Excipients and Drug Metabolism: A Mini-Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218224"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., and He, L. (2021). Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312808"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00204-021-03025-z","article-title":"Metabolism and Interactions of Ivermectin with Human Cytochrome P450 Enzymes and Drug Transporters, Possible Adverse and Toxic Effects","volume":"95","author":"Rendic","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Coelho, M.M., Fernandes, C., Remi\u00e3o, F., and Tiritan, M.E. (2021). Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods. Molecules, 26.","DOI":"10.3390\/molecules26113113"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1208\/aapsj080112","article-title":"Cytochrome P450s and Other Enzymes in Drug Metabolism and Toxicity","volume":"8","author":"Guengerich","year":"2006","journal-title":"AAPS J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1007\/s00018-020-03733-2","article-title":"An Emerging Potential of Metabolomics in Multiple Sclerosis: A Comprehensive Overview","volume":"78","author":"Zahoor","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(90)90006-N","article-title":"Molecular Genetics of the P-450 Superfamily","volume":"45","author":"Gonzalez","year":"1990","journal-title":"Pharmac. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and Individualized Drug Therapy","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.pharmtox.41.1.535","article-title":"Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes","volume":"41","author":"Lin","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","article-title":"The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly A Study of Over 600 000 Elderly Patients from the Swedish Prescribed Drug Register","volume":"30","author":"Johnell","year":"2007","journal-title":"Drug Saf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3399\/bjgp11X556146","article-title":"Polypharmacy: One of the Greatest Prescribing Challenges in General Practice","volume":"61","author":"Payne","year":"2011","journal-title":"Br. J. General. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews","volume":"21","author":"Davies","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_20","first-page":"1728","article-title":"Polypharmacy","volume":"318","author":"Onder","year":"2017","journal-title":"Clin. Pharm. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41256-023-00311-4","article-title":"Prevalence and Trends of Polypharmacy in U.S. Adults, 1999\u20132018","volume":"8","author":"Wang","year":"2023","journal-title":"Glob. Health Res. Policy"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Delara, M., Murray, L., Jafari, B., Bahji, A., Goodarzi, Z., Kirkham, J., Chowdhury, Z., and Seitz, D.P. (2022). Prevalence and Factors Associated with Polypharmacy: A Systematic Review and Meta-Analysis. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03279-x"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/gerona\/glv013","article-title":"Polypharmacy among Adults Aged 65 Years and Older in the United States: 1988\u20132010","volume":"70","author":"Charlesworth","year":"2015","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in Prescription Drug Use among Adults in the United States from 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Alhumaidi, R.M., Bamagous, G.A., Alsanosi, S.M., Alqashqari, H.S., Qadhi, R.S., Alhindi, Y.Z., Ayoub, N., and Falemban, A.H. (2023). Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123960"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lee, J., Beers, J.L., Geffert, R.M., and Jackson, K.D. (2024). A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment. Biomolecules, 14.","DOI":"10.3390\/biom14010099"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Peng, Y., Cheng, Z., and Xie, F. (2021). Evaluation of Pharmacokinetic Drug-Drug Interactions: A Review of the Mechanisms, in Vitro and in Silico Approaches. Metabolites, 11.","DOI":"10.3390\/metabo11020075"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bdd.2212","article-title":"In Vitro and in Vivo Methods to Assess Pharmacokinetic Drug\u2014Drug Interactions in Drug Discovery and Development","volume":"41","author":"Lu","year":"2020","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bcp.15970","article-title":"Drug-Drug Interactions and the Risk of Adverse Drug Reaction-Related Hospital Admissions in the Older Population","volume":"90","author":"Hughes","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/pds.5691","article-title":"A Meta-Analysis Assessing the Prevalence of Drug-Drug Interactions among Hospitalized Patients","volume":"32","author":"Aksoy","year":"2023","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40264-023-01283-7","article-title":"Drug-Drug Interactions and the Risk of Emergency Hospitalizations: A Nationwide Population-Based Study","volume":"46","author":"Bezin","year":"2023","journal-title":"Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in Vivo Drug Interactions from in Vitro Drug Discovery Data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.addr.2013.12.005","article-title":"The Application of 3D Cell Models to Support Drug Safety Assessment: Opportunities & Challenges","volume":"69\u201370","author":"Roth","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_35","unstructured":"Food and Drug Administration (FDA) (2020). In Vitro Interaction Drug Interaction Studies-Cytochrome P450 Enzyme and Transporter Mediated Drug Interactions Final-Center for Evaluation and Research (CDER)."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2174\/1389200033489424","article-title":"Human Hepatocytes as a Tool for Studying Toxicity and Drug Metabolism","volume":"4","author":"Donato","year":"2003","journal-title":"Curr. Drug Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpba.2017.07.023","article-title":"Cell Cultures in Drug Discovery and Development: The Need of Reliable in Vitro-in Vivo Extrapolation for Pharmacodynamics and Pharmacokinetics Assessment","volume":"147","author":"Jaroch","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.apsb.2012.10.004","article-title":"Preclinical Experimental Models of Drug Metabolism and Disposition in Drug Discovery and Development","volume":"2","author":"Zhang","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_39","first-page":"495","article-title":"Application of Pharmaceutical Profiling Assays for Optimization of Drug-like Properties","volume":"8","author":"Di","year":"2005","journal-title":"Curr. Opin. Drug Discov. Devel"},{"key":"ref_40","unstructured":"European Medicines Agency (2012). Guideline on the Investigation of Drug Interactions."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chen, Y., Mao, J., and Fretland, A.J. (2015). Reaction Phenotyping. Encyclopedia of Drug Metabolism and Interactions, John Wiley and Sons.","DOI":"10.1002\/9780470921920.edm140"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/dmd.114.058750","article-title":"Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes","volume":"43","author":"Zientek","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/17425255.3.5.667","article-title":"Cytochrome P450 Reaction-Phenotyping: An Industrial Perspective","volume":"3","author":"Zhang","year":"2007","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/dmd.31.4.345","article-title":"Cytochrome P450 In Vitro Reaction Phenotyping: A Re-Evaluation of Approaches Used for P450 Isoform Identification","volume":"31","author":"Lu","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.medidd.2022.100121","article-title":"Metabolism-Mediated Drug-Drug Interactions\u2014Study Design, Data Analysis, and Implications for in Vitro Evaluations","volume":"14","author":"Fu","year":"2022","journal-title":"Med. Drug Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbi.2007.01.001","article-title":"Human Hepatocytes: Isolation, Cryopreservation and Applications in Drug Development","volume":"168","author":"Li","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and Induction of CYP Enzymes in Humans: An Update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/cclm.1976.14.1-12.527","article-title":"Preparation of Parenchymal and Non-Parenchymal Cells from Adult Human Liver\u2014Morphological and Biochemical Characteristics","volume":"14","author":"Bojar","year":"1976","journal-title":"cclm"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00204-013-1078-5","article-title":"Recent Advances in 2D and 3D in Vitro Systems Using Primary Hepatocytes, Alternative Hepatocyte Sources and Non-Parenchymal Liver Cells and Their Use in Investigating Mechanisms of Hepatotoxicity, Cell Signaling and ADME","volume":"87","author":"Godoy","year":"2013","journal-title":"Arch. Toxicol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0168-8278(99)80049-X","article-title":"Characterization of Drug Metabolizing Activities in Pig Hepatocytes for Use in Bioartifxial Liver Devices: Comparison with Other Hepatic Cellular Models","volume":"31","author":"Donato","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1124\/dmd.105.004762","article-title":"Functional Expression of Sinusoidal Drug Transporters in Primary Human and Rat Hepatocytes","volume":"33","author":"Jigorel","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2016.1125881","article-title":"Opportunities and Challenges in Using Human Hepatocytes in Cytochromes P450 Induction Assays","volume":"12","author":"Dvorak","year":"2016","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0009-2797(97)00070-7","article-title":"Preclinical Evaluation of Drug-Drug Interaction Potential: Present Status of the Application of Primary Human Hepatocytes in the Evaluation of Cytochrome P450 Induction","volume":"107","author":"Li","year":"1997","journal-title":"Chem. Biol. Interact."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/00498250210128675","article-title":"Cytochrome P450 Expression in Human Hepatocytes and Hepatoma Cell Lines: Molecular Mechanisms That Determine Lower Expression in Cultured Cells","volume":"32","author":"Donato","year":"2002","journal-title":"Xenobiotica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1006\/bbrc.1993.2521","article-title":"Alteration of Transcription Factor MRNAs during the Isolation and Culture of Rat Hepatocytes Suggests the Activation of a Proliferative Mode Underlies Their Dedifferentiation","volume":"197","author":"Padgham","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Lecluyse, E., Madan, A., Hamilton, G., Carroll, K., Dehaan, R., and Parkinson, A. (2000). Expression and Regulation of Cytochrome P450 Enzymes in Primary Cultures of Human Hepatocytes Magnitude of Induction, John Wiley and Sons.","DOI":"10.1002\/(SICI)1099-0461(2000)14:4<177::AID-JBT1>3.0.CO;2-4"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-2143(97)90199-2","article-title":"Time-Dependent Expression of Cytochrome P450 Genes in Primary Cultures of Well-Differentiated Human Hepatocytes","volume":"129","author":"George","year":"1997","journal-title":"J. Lab. Clin. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2890621","article-title":"Altered Expression of Cytochrome P-450 MRNAs, and Potentially of Other Transcripts Encoding Key Hepatic Functions, Are Triggered during the Isolation of Rat Hepatocytes","volume":"289","author":"Padgham","year":"1993","journal-title":"Biochem. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/1389200043335414","article-title":"Human Hepatocytes in Primary Culture: The Choice to Investigate Drug Metabolism in Man","volume":"5","author":"Donato","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF02577575","article-title":"Optimization of culture conditions for determining hepatobiliary disposition of taurocholate in sandwich-cultured rat hepatocytes","volume":"37","author":"Chandra","year":"2001","journal-title":"Vitr. Cell. Dev. Biol. Anim."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kaur, I., Vasudevan, A., Rawal, P., Tripathi, D.M., Ramakrishna, S., Kaur, S., and Sarin, S.K. (2023). Primary Hepatocyte Isolation and Cultures: Technical Aspects, Challenges and Advancements. Bioengineering, 10.","DOI":"10.3390\/bioengineering10020131"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Nelson, L.J., Treskes, P., Howie, A.F., Walker, S.W., Hayes, P.C., and Plevris, J.N. (2013). Profiling the Impact of Medium Formulation on Morphology and Functionality of Primary Hepatocytes in Vitro. Sci. Rep., 3.","DOI":"10.1038\/srep02735"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3748\/wjg.v10.i5.699","article-title":"Primary Hepatocyte Culture in Collagen Gel Mixture and Collagen Sandwich","volume":"10","author":"Wang","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1096\/fasebj.3.2.2914628","article-title":"Hepatocyte Function and Extracellular Matrix Geometry: Long-Term Culture in a Sandwich Configuration","volume":"3","author":"Dunn","year":"1989","journal-title":"FASEB J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/dmd.115.067900","article-title":"Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism","volume":"44","author":"Tracy","year":"2016","journal-title":"Drug Metab Dispos."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00204-011-0733-y","article-title":"Comparative Analysis of Phase i and II Enzyme Activities in 5 Hepatic Cell Lines Identifies Huh-7 and HCC-T Cells with the Highest Potential to Study Drug Metabolism","volume":"86","author":"Lin","year":"2012","journal-title":"Arch. Toxicol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Sanchez-Quant, E., Richter, M.L., Colom\u00e9-Tatch\u00e9, M., and Martinez-Jimenez, C.P. (2023). Single-Cell Metabolic Profiling Reveals Subgroups of Primary Human Hepatocytes with Heterogeneous Responses to Drug Challenge. Genome Biol., 24.","DOI":"10.1186\/s13059-023-03075-9"},{"key":"ref_68","first-page":"1042","article-title":"Studies Comparing in Vivo:In Vitro Metabolism of Three Pharmaceutical Compounds in Rat, Dog, Monkey, and Human Using Cryopreserved Hepatocytes, Microsomes, and Collagen Gel Immobilized Hepatocyte Cultures","volume":"29","author":"Hewitt","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0009-2797(99)00089-7","article-title":"Comparative Effects of Rifabutin and Rifampicin on Cytochromes P450 and UDP-Glucuronosyl-Transferases Expression in Fresh and Cryopreserved Human Hepatocytes","volume":"121","author":"Reinach","year":"1999","journal-title":"Chem. Biol. Interact."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/13813455.2012.683442","article-title":"The Human Hepatocyte Cell Lines IHH and HepaRG: Models to Study Glucose, Lipid and Lipoprotein Metabolism","volume":"118","author":"Samanez","year":"2012","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_71","first-page":"465","article-title":"Integrated Cytochrome P450 Reaction Phenotyping attempting to bridge the gap between cdna-expressed cytochromes p450 and native human liver microsomes","volume":"57","author":"Rodrigues","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The Conduct of in Vitro and in Vivo Drug-Drug Interaction Studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) Perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920007782798207","article-title":"The Conduct of Drug Metabolism Studies Considered Good Practice (II): In Vitro Experiments","volume":"8","author":"Jia","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s12010-009-8689-6","article-title":"Role of Human Liver Microsomes in in Vitro Metabolism of Drugs-A Review","volume":"160","author":"Asha","year":"2010","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0009-2797(74)80005-0","article-title":"Cytochrome P-450-Linked Monooxygenase System and Drug-Induced Spectral Interactions in Human Liver Microsomes","volume":"9","author":"Pelkonen","year":"1974","journal-title":"Chem. Biol. Interact."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ddtec.2005.05.024","article-title":"Preclinical in Vitro Screening Assays for Drug-like Properties","volume":"2","author":"Li","year":"2005","journal-title":"Drug Discov. Today Technol."},{"key":"ref_77","first-page":"47","article-title":"6\u03b1-Hydroxylation of Taurochenodeoxycholic Acid and Lithocholic Acid by CYP3A4 in Human Liver Microsomes","volume":"1438","author":"Araya","year":"1999","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.taap.2004.01.010","article-title":"The Effects of Gender, Age, Ethnicity, and Liver Cirrhosis on Cytochrome P450 Enzyme Activity in Human Liver Microsomes and Inducibility in Cultured Human Hepatocytes","volume":"199","author":"Parkinson","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1087057103255988","article-title":"Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates","volume":"8","author":"Di","year":"2003","journal-title":"SLAS Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/abbi.1996.0294","article-title":"Effects of Freezing, Thawing, and Storing Human Liver Microsomes on Cytochrome P450 Activity","volume":"331","author":"Pearce","year":"1996","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.tiv.2024.105922","article-title":"Cytochrome P450-Mediated Metabolic Interactions between Donepezil and Tadalafil in Human Liver Microsomes","volume":"100","author":"Yu","year":"2024","journal-title":"Toxicol. Vitr."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Liu, S., Wang, Z., Chan, E., Zhao, Y., Kang, J., Zhang, X., and Tian, X. (2022). Inhibition of Cytochrome P450 Enzymes and Uridine 5\u2032-Diphospho-Glucuronosyltransferases by Vicagrel in Human Liver Microsomes: A Prediction of Potential Drug-Drug Interactions. Chem. Biol. Interact., 352.","DOI":"10.1016\/j.cbi.2021.109775"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/00498254.2018.1524186","article-title":"Evaluation of Pharmacokinetic Interactions between Bicyclol and Co-Administered Drugs in Rat and Human Liver Microsomes in Vitro and in Rats in Vivo","volume":"49","author":"Yang","year":"2019","journal-title":"Xenobiotica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e19313","DOI":"10.7717\/peerj.19313","article-title":"Inhibitory Effect of Carvedilol on Bedaquiline Metabolism in Vitro and in Vivo","volume":"13","author":"Li","year":"2025","journal-title":"PeerJ"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Faison, S.L., Batonga, J., Arumugham, T., Bartkus, A., Morrison, M.E., Mullin, M.J., Tippin, T., and Naderer, O. (2025). A Phase 1, Randomized, Crossover Trial to Assess the Effect of Itraconazole on the Pharmacokinetics of Dordaviprone in Healthy Adults. Br. J. Clin. Pharmacol.","DOI":"10.1002\/bcp.70080"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00498254.2025.2498696","article-title":"Cannabidiol Metabolism in Vitro: The Role of Antiseizure Medications and CYP2C19 Genotypes","volume":"10","author":"Jaisupa","year":"2025","journal-title":"Xenobiotica"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01478885.2023.2170772","article-title":"Cell Culture: In Vitro Model System and a Promising Path to in Vivo Applications","volume":"46","author":"Zhao","year":"2023","journal-title":"J. Histotechnol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1177\/1535370216657448","article-title":"Cell Sources for in Vitro Human Liver Cell Culture Models","volume":"241","author":"Zeilinger","year":"2016","journal-title":"Exp. Biol. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JCB-189013","article-title":"HepG2 Cells with Recombinant Cytochrome P450 Enzyme Overexpression: Their Use and Limitation as in Vitro Liver Model","volume":"5","author":"Steinbrecht","year":"2019","journal-title":"J. Cell Biotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.taap.2007.03.032","article-title":"Gene Expression Profiling and Differentiation Assessment in Primary Human Hepatocyte Cultures, Established Hepatoma Cell Lines, and Human Liver Tissues","volume":"222","author":"Olsavsky","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/dmd.110.035873","article-title":"Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes","volume":"39","author":"Guo","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Dannenberg, L.O., and Edenberg, H.J. (2006). Epigenetics of Gene Expression in Human Hepatoma Cells: Expression Profiling the Response to Inhibition of DNA Methylation and Histone Deacetylation. BMC Genom., 7.","DOI":"10.1186\/1471-2164-7-181"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in Human Disease and Prospects for Epigenetic Therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","article-title":"Hep G2 Is a Hepatoblastoma-Derived Cell Line","volume":"40","author":"Cheung","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Arzumanian, V.A., Kiseleva, O.I., and Poverennaya, E.V. (2021). The Curious Case of the HepG2 Cell Line: 40 Years of Expertise. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313135"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Donato, M.T., Tolosa, L., and G\u00f3mez-Lech\u00f3n, M.J. (2015). Culture and Functional Characterization of Human Hepatoma HepG2 Cells. Protocols in In Vitro Hepatocyte Research, Springer.","DOI":"10.1007\/978-1-4939-2074-7_5"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/282615a0","article-title":"Controlled Synthesis of HBsAg in a Differentiated Human Liver Carcinoma-Derived Cell Line","volume":"282","author":"Aden","year":"1979","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/jmcb\/mjaa013","article-title":"Progress in Human Liver Organoids","volume":"12","author":"Sun","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/cncr.10724","article-title":"Hepatoblastoma: Cytomorphologic Characteristics in Serious Cavity Fluids","volume":"96","author":"Weir","year":"2002","journal-title":"Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jprot.2016.01.016","article-title":"In-Depth Quantitative Analysis and Comparison of the Human Hepatocyte and Hepatoma Cell Line HepG2 Proteomes","volume":"136","author":"Vildhede","year":"2016","journal-title":"J. Proteom."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1021\/acs.jproteome.5b00334","article-title":"Comparative Proteomic Analysis of Human Liver Tissue and Isolated Hepatocytes with a Focus on Proteins Determining Drug Exposure","volume":"14","author":"Vildhede","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.tiv.2007.05.014","article-title":"Cytochrome P450 Enzyme Levels in HepG2 Cells and Cryopreserved Primary Human Hepatocytes and Their Induction in HepG2 Cells","volume":"21","author":"Westerink","year":"2007","journal-title":"Toxicol. Vitr."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.tiv.2007.06.017","article-title":"Phase II Enzyme Levels in HepG2 Cells and Cryopreserved Primary Human Hepatocytes and Their Induction in HepG2 Cells","volume":"21","author":"Westerink","year":"2007","journal-title":"Toxicol. Vitr."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-5793(88)81021-4","article-title":"The Influence of Culture Medium Composition on Drug Metabolising Enzyme Activities of the Human Liver Derived Hep G2 Cell Line","volume":"241","author":"Doostdar","year":"1988","journal-title":"FEBS Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jbt.10085","article-title":"Influence of Culture Time on the Expression of Drug-metabolizing Enzymes in Primary Human Hepatocytes and Hepatoma Cell Line HepG2","volume":"17","author":"Wilkening","year":"2003","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/00498250310001657568","article-title":"Phase I and II Enzyme Characterization of Two Sources of HepG2 Cell Lines","volume":"34","author":"Hewitt","year":"2004","journal-title":"Xenobiotica"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2133\/dmpk.24.209","article-title":"Simultaneous Expression of Plural Forms of Human Cytochrome P450 at Desired Ratios in HepG2 Cells: Adenovirus-Mediated Tool for Cytochrome P450 Reconstitution","volume":"24","author":"Aoyama","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tox.2005.08.003","article-title":"An in Vitro Approach to Detect Metabolite Toxicity Due to CYP3A4-Dependent Bioactivation of Xenobiotics","volume":"216","author":"Vignati","year":"2005","journal-title":"Toxicology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1124\/dmd.110.037077","article-title":"Development of a Highly Sensitive Cytotoxicity Assay System for CYP3A4-Mediated Metabolic Activation","volume":"39","author":"Hosomi","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/dmd.110.037259","article-title":"CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay","volume":"39","author":"Iwamura","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1124\/dmd.110.033605","article-title":"Metabolite Formation Kinetics and Intrinsic Clearance of Phenacetin, Tolbutamide, Alprazolam, and Midazolam in Adenoviral Cytochrome P450-Transfected HepG2 Cells and Comparison with Hepatocytes and In Vivo","volume":"38","author":"Donato","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/B:MCBI.0000038232.61760.9e","article-title":"Adenovirus Mediated Overexpression of CYP2E1 Increases Sensitivity of HepG2 Cells to Acetaminophen Induced Cytotoxicity","volume":"262","author":"Bai","year":"2004","journal-title":"Mol. Cell Biochem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00204-013-1012-x","article-title":"HepG2 Cells Simultaneously Expressing Five P450 Enzymes for the Screening of Hepatotoxicity: Identification of Bioactivable Drugs and the Potential Mechanism of Toxicity Involved","volume":"87","author":"Tolosa","year":"2013","journal-title":"Arch. Toxicol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4161\/cbt.7.8.6283","article-title":"Overexpression of CYP2E1 Enhances Sensitivity of HepG2 Cells to Fas-Mediated Cytotoxicity","volume":"7","author":"Yan","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2174\/1389200211314090002","article-title":"Hepatic Cell Lines for Drug Hepatotoxicity Testing: Limitations and Strategies to Upgrade Their Metabolic Competence by Gene Engineering","volume":"14","author":"Donato","year":"2013","journal-title":"Curr. Drug Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.tiv.2011.11.008","article-title":"Upgrading Cytochrome P450 Activity in HepG2 Cells Co-Transfected with Adenoviral Vectors for Drug Hepatotoxicity Assessment","volume":"26","author":"Tolosa","year":"2012","journal-title":"Toxicol. Vitr."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/26896583.2021.1880242","article-title":"Characterization of Cytochrome P450s (CYP)-Overexpressing HepG2 Cells for Assessing Drug and Chemical-Induced Liver Toxicity","volume":"39","author":"Chen","year":"2021","journal-title":"J. Environ. Sci. Health Part C"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0006-2952(99)00167-7","article-title":"Hepatic Metabolism of Diclofenac: Role of Human CYP in the Minor Oxidative Pathways","volume":"58","author":"Bort","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JCB-15002","article-title":"Generation of Cytochrome P450 3A4-Overexpressing HepG2 Cell Clones for Standardization of Hepatocellular Testosterone 6\u03b2-Hydroxylation Activity","volume":"1","author":"Herzog","year":"2015","journal-title":"J. Cell Biotechnol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cbi.2015.10.009","article-title":"Development of HepG2-Derived Cells Expressing Cytochrome P450s for Assessing Metabolism-Associated Drug-Induced Liver Toxicity","volume":"255","author":"Xuan","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tiv.2016.11.006","article-title":"Metabolic-Induced Cytotoxicity of Diosbulbin B in CYP3A4-Expressing Cells","volume":"38","author":"Jiang","year":"2017","journal-title":"Toxicol. Vitr."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Chiang, T.-S., Yang, K.-C., Chiou, L.-L., Huang, G.-T., and Lee, H.-S. (2014). Enhancement of CYP3A4 Activity in Hep G2 Cells by Lentiviral Transfection of Hepatocyte Nuclear Factor-1 Alpha. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094885"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Nakamura, K., Aizawa, K., Aung, K.H., Yamauchi, J., and Tanoue, A. (2017). Zebularine Upregulates Expression of CYP Genes through Inhibition of DNMT1 and PKR in HepG2 Cells. Sci. Rep., 7.","DOI":"10.1038\/srep41093"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Ruo\u00df, M., Damm, G., Vosough, M., Ehret, L., Grom-Baumgarten, C., Petkov, M., Naddalin, S., Ladurner, R., Seehofer, D., and Nussler, A. (2019). Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020347"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/a-2111-6649","article-title":"Altered Gene Expression of Cytochrome P450 and ABC Transporter in Human Hepatocellular Carcinoma HepG2 Cells Exposed to Bardoxolone Methyl","volume":"73","author":"Nagai","year":"2023","journal-title":"Drug Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1534\/genetics.111.136911","article-title":"Gene Overexpression: Uses, Mechanisms, and Interpretation","volume":"190","author":"Prelich","year":"2012","journal-title":"Genetics"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/00498254.2024.2421513","article-title":"Notable Drug-Drug Interaction between Omeprazole and Voriconazole in CYP2C19 *1 and *2 (Rs4244285, 681G&gt;A) Alleles in Vitro","volume":"54","author":"Li","year":"2024","journal-title":"Xenobiotica"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Xun, T., Rong, Y., Lv, B., Tian, J., Zhang, Q., and Yang, X. (2023). Interaction and Potential Mechanisms between Atorvastatin and Voriconazole, Agents Used to Treat Dyslipidemia and Fungal Infections. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1165950"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2016.11.007","article-title":"In Vitro to in Vivo Extrapolation of the Complex Drug-Drug Interaction of Bupropion and Its Metabolites with CYP2D6; Simultaneous Reversible Inhibition and CYP2D6 Downregulation","volume":"123","author":"Sager","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Cui, H., Wang, J., Zhang, Q., Dang, M., Liu, H., Dong, Y., Zhang, L., Yang, F., Wu, J., and Tong, X. (2016). In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies. Molecules, 21.","DOI":"10.3390\/molecules21040464"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.2012.685159","article-title":"The HepaRG Cell Line: A Unique in Vitro Tool for Understanding Drug Metabolism and Toxicology in Human","volume":"8","author":"Andersson","year":"2012","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.tiv.2009.03.008","article-title":"Functional Expression, Inhibition and Induction of CYP Enzymes in HepaRG Cells","volume":"23","author":"Turpeinen","year":"2009","journal-title":"Toxicol. Vitr."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a Human Hepatoma Cell Line by Hepatitis B Virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of Cytochromes P450, Conjugating Enzymes and Nuclear Receptors in Human Hepatoma HepaRG Cells","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.21536","article-title":"Transdifferentiation of Hepatocyte-like Cells from the Human Hepatoma HepaRG Cell Line through Bipotent Progenitor\u2020","volume":"45","author":"Cerec","year":"2007","journal-title":"Hepatology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.tiv.2012.05.008","article-title":"Optimization of the HepaRG Cell Model for Drug Metabolism and Toxicity Studies","volume":"26","author":"Li","year":"2012","journal-title":"Toxicol. Vitr."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The Human Hepatoma HepaRG Cells: A Highly Differentiated Model for Studies of Liver Metabolism and Toxicity of Xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/toxsci\/kfv136","article-title":"Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication","volume":"147","author":"Mitsa","year":"2015","journal-title":"Toxicol. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2004.01.002","article-title":"Origin and Characterization of a Human Bipotent Liver Progenitor Cell Line","volume":"126","author":"Parent","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1248\/bpb.b17-00913","article-title":"Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures","volume":"41","author":"Yokoyama","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1124\/dmd.109.031831","article-title":"A Comparison of Whole Genome Gene Expression Profiles of HepaRG Cells and HepG2 Cells to Primary Human Hepatocytes and Human Liver Tissues","volume":"38","author":"Hart","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1074\/jbc.M107228200","article-title":"Transcriptional Regulation of CYP2C9 Gene","volume":"277","author":"Daujat","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vascn.2010.04.013","article-title":"HepaRG Human Hepatic Cell Line Utility as a Surrogate for Primary Human Hepatocytes in Drug Metabolism Assessment in Vitro","volume":"63","author":"Mayer","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/dmd.107.017418","article-title":"HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1124\/dmd.107.019901","article-title":"Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies","volume":"36","author":"Aninat","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1124\/dmd.109.030197","article-title":"Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Dubois-Pot-Schneider, H., Aninat, C., Kattler, K., Fekir, K., Jarnouen, K., Cerec, V., Glaise, D., Salhab, A., Gasparoni, G., and Takashi, K. (2022). Transcriptional and Epigenetic Consequences of DMSO Treatment on HepaRG Cells. Cells, 11.","DOI":"10.3390\/cells11152298"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10517-016-3360-z","article-title":"Maintenance of High Cytochrome P450 Expression in HepaRG Cell Spheroids in DMSO-Free Medium","volume":"161","author":"Aleksandrova","year":"2016","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00204-014-1320-9","article-title":"HepaRG Microencapsulated Spheroids in DMSO-Free Culture: Novel Culturing Approaches for Enhanced Xenobiotic and Biosynthetic Metabolism","volume":"89","author":"Rebelo","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Wang, Z.-Y., Li, W.-J., Li, Q.-G., Jing, H.-S., Yuan, T.-J., Fu, G.-B., Tang, D., Zhang, H.-D., Yan, H.-X., and Zhai, B. (2019). A DMSO-Free Hepatocyte Maturation Medium Accelerates Hepatic Differentiation of HepaRG Cells in Vitro. Biomed. Pharmacother., 116.","DOI":"10.1016\/j.biopha.2019.109010"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00204-016-1745-4","article-title":"A Multicenter Assessment of Single-Cell Models Aligned to Standard Measures of Cell Health for Prediction of Acute Hepatotoxicity","volume":"91","author":"Lauschke","year":"2017","journal-title":"Arch. Toxicol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00204-022-03329-8","article-title":"Optimisation of the HepaRG Cell Line Model for Drug Toxicity Studies Using Two Different Cultivation Conditions: Advantages and Limitations","volume":"96","author":"Hammour","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_153","first-page":"10183","article-title":"Differentiation of HepaRG Cells into Hepatocytes Based on Substrate Elasticity","volume":"11","author":"Li","year":"2018","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Gomes, J.V.D., Herz, C., Helmig, S., F\u00f6rster, N., Mewis, I., and Lamy, E. (2021). Drug-Drug Interaction Potential, Cytotoxicity, and Reactive Oxygen Species Production of Salix Cortex Extracts Using Human Hepatocyte-Like HepaRG Cells. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.779801"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"105389","DOI":"10.1016\/j.tiv.2022.105389","article-title":"Study of the Metabolic Stability Profiles of Perampanel, Rufinamide and Stiripentol and Prediction of Drug Interactions Using HepaRG Cells as an in Vitro Human Model","volume":"82","author":"Meirinho","year":"2022","journal-title":"Toxicol. Vitr."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1046\/j.1432-1327.2001.02011.x","article-title":"Expression and Induction of a Large Set of Drug-metabolizing Enzymes by the Highly Differentiated Human Hepatoma Cell Line BC2","volume":"268","author":"Donato","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"ref_157","first-page":"165","article-title":"Cell Cycle Gene Regulation in Reversibly Differentiated New Human Hepatoma Cell Lines","volume":"9","author":"Glaise","year":"1998","journal-title":"Cell Growth Differ."},{"key":"ref_158","first-page":"10183","article-title":"A New Hepatoma Cell Line for Toxicity Testing at Repeated Doses","volume":"19","author":"Fabre","year":"2003","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_159","first-page":"113","article-title":"A New Human Hepatoma Cell Line to Study Repeated Cell Toxicity","volume":"32","author":"Fabre","year":"2004","journal-title":"Altern. Lab. Anim."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbrc.2014.08.068","article-title":"Molecular Mechanism of an Adverse Drug-Drug Interaction of Allopurinol and Furosemide in Gout Treatment","volume":"452","author":"Knake","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.tiv.2014.08.004","article-title":"HepaRG Cell Line as an in Vitro Model for Screening Drug-Drug Interactions Mediated by Metabolic Induction: Amiodarone Used as a Model Substance","volume":"28","author":"Ferreira","year":"2014","journal-title":"Toxicol. Vitr."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e00161","DOI":"10.1002\/prp2.161","article-title":"Applicability of Second-generation Upcyte \u00ae Human Hepatocytes for Use in CYP Inhibition and Induction Studies","volume":"3","author":"Ramachandran","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/molpharm.120.000223","article-title":"Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells","volume":"100","author":"Harati","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Tian, S., Su, R., Wu, K., Zhou, X., Vadgama, J.V., and Wu, Y. (2022). Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells. J. Pers. Med., 12.","DOI":"10.3390\/jpm12081318"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1038\/ncomms4739","article-title":"High-Throughput and Combinatorial Gene Expression on a Chip for Metabolism-Induced Toxicology Screening","volume":"5","author":"Kwon","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0022-3565(25)38136-X","article-title":"Specificity of Substrate and Inhibitor Probes for Human Cytochromes P450 1A1 and 1A2","volume":"265","author":"Tassaneeyakul","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/abbi.1993.1588","article-title":"Enzyme-Kinetic and Immunochemical Characteristics of Mouse CDNA-Expressed, Microsomal, and Purified CYP1A1 and CYP1A2","volume":"307","author":"Tsyrlov","year":"1993","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/carcin\/11.7.1183","article-title":"Differential Expression and Regulation of Members of the Cytochrome P450IA Gene Subfamily in Human Tissues","volume":"11","author":"Sesardic","year":"1990","journal-title":"Carcinogenesis"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/tx00035a009","article-title":"Isoform-Selective Mechanism-Based Inhibition of Human Cytochrome P450 1A2 by Furafylline","volume":"6","author":"Kunze","year":"1993","journal-title":"Chem. Res. Toxicol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/00498259409043254","article-title":"Characterization of the Inhibition of P4501A2 by Furafylline","volume":"24","author":"Clarke","year":"1994","journal-title":"Xenobiotica"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1021\/tx00042a018","article-title":"Lauric Acid as a Model Substrate for the Simultaneous Determination of Cytochrome P450 2E1 and 4A in Hepatic Microsomes","volume":"7","author":"Clarke","year":"1994","journal-title":"Chem. Res. Toxicol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.103.056127","article-title":"Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine","volume":"308","author":"Richter","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","article-title":"Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation","volume":"77","author":"Turpeinen","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/TCRM.S80437","article-title":"Pharmacokinetic Drug Interactions with Clopidogrel: Updated Review and Risk Management in Combination Therapy","volume":"11","author":"Zhou","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 Mediates the in Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/00498254.2017.1354267","article-title":"Quantitative in Vitro Phenotyping and Prediction of Drug Interaction Potential of CYP2B6 Substrates as Victims","volume":"48","author":"Palacharla","year":"2018","journal-title":"Xenobiotica"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/dmd.30.5.525","article-title":"Triethylenethiophosphoramide Is a Specific Inhibitor of Cytochrome P450 2B6: Implications for Cyclophosphamide Metabolism","volume":"30","author":"Rae","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/jpet.104.069112","article-title":"Metabolism of N,N\u2032,N\u2033-Triethylenethiophosphoramide by CYP2B1 and CYP2B6 Results in the Inactivation of Both Isoforms by Two Distinct Mechanisms","volume":"310","author":"Harleton","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/dmd.32.6.626","article-title":"Selective inhibition of cyp2b6-catalyzed bupropion hydroxylation in human liver microsomes in vitro","volume":"32","author":"Turpeinen","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bcp.2004.10.008","article-title":"Inhibition of Human CYP2B6 by N,N\u2032,N\u2033-Triethylenethiophosphoramide Is Irreversible and Mechanism-Based","volume":"69","author":"Richter","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cbi.2013.06.006","article-title":"Potent Inhibition of Cytochrome P450 2B6 by Sibutramine in Human Liver Microsomes","volume":"205","author":"Bae","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejps.2004.10.006","article-title":"Multiple P450 Substrates in a Single Run: Rapid and Comprehensive in Vitro Interaction Assay","volume":"24","author":"Turpeinen","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1124\/dmd.30.12.1352","article-title":"Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes","volume":"30","author":"Wang","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1742-7843.2005.pto_157.x","article-title":"Metabolism of Repaglinide by CYP2C8 and CYP3A4 In Vitro: Effect of Fibrates and Rifampicin","volume":"97","author":"Kajosaari","year":"2005","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of cyp2c8: Implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1124\/dmd.118.085498","article-title":"Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8","volume":"47","author":"Kahma","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","article-title":"Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8","volume":"45","author":"Walsky","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.104.002766","article-title":"Selective inhibition of human cytochrome p4502c8 by montelukast","volume":"33","author":"Walsky","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/dmd.115.069096","article-title":"Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions\u2014An Industry Perspective","volume":"44","author":"Bohnert","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1988.tb03359.x","article-title":"In Vitro Inhibition Studies of Tolbutamide Hydroxylase Activity of Human Liver Microsomes by Azoles, Sulphonamides and Quinolines","volume":"26","author":"Back","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(25)12826-7","article-title":"Cytochrome P450 Isoform Inhibitors as a Tool for the Investigation of Metabolic Reactions Catalyzed by Human Liver Microsomes","volume":"277","author":"Meunier","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/00498259509061850","article-title":"Ketoconazole and Sulphaphenazole as the Respective Selective Inhibitors of P4503A and 2C9","volume":"25","author":"Baldwin","year":"1995","journal-title":"Xenobiotica"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/dmd.108.023358","article-title":"Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (\u00b1)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection","volume":"37","author":"Hutzler","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-Benzyl-Nirvanol and (\u2212)-N-3-Benzyl-Phenobarbital: New Potent and Selective in Vitro Inhibitors of CYP2C19","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_196","first-page":"1173","article-title":"In Vitro Characterization of the Inhibition Profile of Loratadine, Desloratadine, and 3-OH-Desloratadine for Five Human Cytochrome P-450 Enzymes","volume":"29","author":"Barecki","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/abbi.2000.1835","article-title":"Inhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450","volume":"378","author":"Tassaneeyakul","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"12112","DOI":"10.1021\/bi010254c","article-title":"Ticlopidine as a Selective Mechanism-Based Inhibitor of Human Cytochrome P450 2C19","volume":"40","author":"Dijols","year":"2001","journal-title":"Biochemistry"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2125.2000.00175.x","article-title":"In Vitro Inhibition of the Cytochrome P450 (CYP450) System by the Antiplatelet Drug Ticlopidine: Potent Effect on CYP2C19 and CYP2D6","volume":"49","author":"Ko","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/138920006778520633","article-title":"The Functional Role of CYP2B6 in Human Drug Metabolism: Substrates and Inhibitors In Vitro, In Vivo and In Silico","volume":"7","author":"Turpeinen","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","article-title":"The Effect of Selective Serotonin Re-uptake Inhibitors on Cytochrome P4502D6 (CYP2D6) Activity in Human Liver Microsomes","volume":"34","author":"Crewe","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2125.1995.tb05793.x","article-title":"The Effects of Selective Serotonin Reuptake Inhibitors and Their Metabolites on S-mephenytoin 4\u2032-hydroxylase Activity in Human Liver Microsomes","volume":"40","author":"Kobayashi","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/(SICI)1099-081X(199704)18:3<227::AID-BDD18>3.0.CO;2-L","article-title":"Metabolism of Dextromethorphanin Vitro: Involvement of Cytochromes P450 2D6 AND 3A3\/4, with a Possible Role of 2E1","volume":"18","author":"Schmider","year":"1997","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.1989.tb03502.x","article-title":"Effect of Quinidine on the Dextromethorphan O-demethylase Activity of Microsomal Fractions from Human Liver","volume":"28","author":"Broly","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0024-3205(84)90332-1","article-title":"Competitive Inhibition of Sparteine Oxidation in Human Liver by \u03b2-Adrenoceptor Antagonists and Other Cardiovascular Drugs","volume":"34","author":"Otton","year":"1984","journal-title":"Life Sci."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0090-9556(25)06891-6","article-title":"In Vitro Evidence against the Oxidation of Quinidine by the Sparteine\/Debrisoquine Monooxygenase of Human Liver","volume":"16","author":"Otton","year":"1988","journal-title":"Drug Metab. Dispos."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/00498254.2016.1208854","article-title":"Direct and Quantitative Evaluation of the Human CYP3A4 Contribution (f m) to Drug Clearance Using the In Vitro SILENSOMES Model","volume":"47","author":"Parmentier","year":"2017","journal-title":"Xenobiotica"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/dmd.32.1.105","article-title":"Highly selective inhibition of human cyp3a in vitro by azamulin and evidence that inhibition is irreversible","volume":"32","author":"Stresser","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in cyp3a4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0022-3565(25)12284-2","article-title":"Triazolam Biotransformation by Human Liver Microsomes in Vitro: Effects of Metabolic Inhibitors and Clinical Confirmation of a Predicted Interaction with Ketoconazole","volume":"276","author":"Greenblatt","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1124\/dmd.118.081828","article-title":"Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method","volume":"46","author":"Yoshida","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-9556(25)06500-6","article-title":"Cytochrome P450 Inhibitors. Evaluation of Specificities in the in Vitrometabolism of Therapeutic Agents by Human Liver Microsomes","volume":"23","author":"Newton","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-2952(98)00133-6","article-title":"Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes","volume":"56","author":"Yamazaki","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/00498250500446208","article-title":"Comparative Analysis of Substrate and Inhibitor Interactions with CYP3A4 and CYP3A5","volume":"36","author":"Soars","year":"2006","journal-title":"Xenobiotica"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2125.2001.01386.x","article-title":"Inhibitory Effects of Verapamil and Diltiazem on Simvastatin Metabolism in Human Liver Microsomes","volume":"51","author":"Yeo","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/dmd.104.001834","article-title":"DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL","volume":"33","author":"Wang","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_218","first-page":"601","article-title":"Pharmacokinetic Drug-Drug Interaction and Their Implication in Clinical Management","volume":"18","author":"Palleria","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00543794","article-title":"Time Course of Phenobarbital and Cimetidine Mediated Changes in Hepatic Drug Metabolism","volume":"25","author":"Pilsgaard","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1440-1681.1997.tb01228.x","article-title":"Drug-Mediated Inactivation of Cytochrome P450","volume":"24","author":"Murray","year":"1997","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_221","unstructured":"European Medicines Agency (2024). ICH M12 Guideline on Drug Interaction Studies."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Deodhar, M., Al Rihani, S.B., Arwood, M.J., Darakjian, L., Dow, P., Turgeon, J., and Michaud, V. (2020). Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090846"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-62703-758-7_4","article-title":"Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance","volume":"1113","author":"Ring","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and Induction of Cytochrome P450 and the Clinical Implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-1-62703-758-7_2","article-title":"Fundamentals of Enzyme Kinetics","volume":"1113","author":"Seibert","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tiv.2007.11.020","article-title":"Assessment of Drug-Drug Interaction for Silymarin","volume":"22","author":"Doehmer","year":"2008","journal-title":"Toxicol. Vitr."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3109\/00498254.2012.751141","article-title":"A Simplified Approach to Predict CYP3A-Mediated Drug-Drug Interactions at Early Drug Discovery: Validation with Clinical Data","volume":"43","author":"Rioux","year":"2013","journal-title":"Xenobiotica"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1023\/A:1011077109233","article-title":"Inhibition of in Vitro Metabolism of Simvastatin by Itraconazole in Humans and Prediction of in Vivo Drug-Drug Interactions","volume":"18","author":"Ishigam","year":"2001","journal-title":"Pharm. Res."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/00498254.2017.1344911","article-title":"In Vitro Drug-Drug Interactions of Budesonide: Inhibition and Induction of Transporters and Cytochrome P450 Enzymes","volume":"48","author":"Chen","year":"2018","journal-title":"Xenobiotica"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.crtox.2021.05.006","article-title":"Pre-Clinical Drug-Drug Interaction (DDI) of Gefitinib or Erlotinib with Cytochrome P450 (CYP) Inhibiting Drugs, Fluoxetine and\/or Losartan","volume":"2","author":"Luong","year":"2021","journal-title":"Curr. Res. Toxicol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1023\/A:1007451911843","article-title":"Applications of Primary Human Hepatocytes in the Evaluation of Pharmacokinetic Drug-Drug Interactions: Evaluation of Model Drugs Terfenadine and Rifampin","volume":"13","author":"Li","year":"1997","journal-title":"Cell Biol. Toxicol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/bcp.12723","article-title":"Human Hepatocyte Assessment of Imatinib Drug-Drug Interactions\u2014Complexities in Clinical Translation","volume":"80","author":"Beumer","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The Human Intestinal Cytochrome P450 \u201cPie\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejmech.2012.06.043","article-title":"Mechanistic Insights from Comparing Intrinsic Clearance Values between Human Liver Microsomes and Hepatocytes to Guide Drug Design","volume":"57","author":"Di","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"105541","DOI":"10.1016\/j.ejps.2020.105541","article-title":"Mechanistic Insights on Clearance and Inhibition Discordance between Liver Microsomes and Hepatocytes When Clearance in Liver Microsomes Is Higher than in Hepatocytes","volume":"155","author":"Keefer","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1124\/dmd.108.024810","article-title":"Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions","volume":"37","author":"Stringer","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.21608\/ejchem.2024.336321.10804","article-title":"Biochemical Pathways in Drug-Drug Interactions: A Pharmacological Perspective for Enhanced Drug Safety and Efficacy-Cytochrome Inhibition Mechanisms","volume":"67","author":"Alalyani","year":"2024","journal-title":"Egypt. J. Chem."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Parmentier, Y., Bossant, M.-J., Bertrand, M., and Walther, B. (2007). In Vitro Studies of Drug Metabolism. Comprehensive Medicinal Chemistry II, Elsevier.","DOI":"10.1016\/B0-08-045044-X\/00125-5"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1517\/17425255.4.7.837","article-title":"An Update on Metabolism Studies Using Human Hepatocytes in Primary Culture","volume":"4","author":"Castell","year":"2008","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Bouwmeester, M.C., Tao, Y., Proen\u00e7a, S., van Steenbeek, F.G., Samsom, R.-A., Nijmeijer, S.M., Sinnige, T., van der Laan, L.J.W., Legler, J., and Schneeberger, K. (2023). Drug Metabolism of Hepatocyte-like Organoids and Their Applicability in In Vitro Toxicity Testing. Molecules, 28.","DOI":"10.3390\/molecules28020621"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/03602532.2021.1922435","article-title":"Recent Developments in in Vitro and in Vivo Models for Improved Translation of Preclinical Pharmacokinetics and Pharmacodynamics Data","volume":"53","author":"Yadav","year":"2021","journal-title":"Drug Metab. Rev."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2013.01.012","article-title":"A Long-Term Three Dimensional Liver Co-Culture System for Improved Prediction of Clinically Relevant Drug-Induced Hepatotoxicity","volume":"268","author":"Kostadinova","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1016\/j.biomaterials.2012.08.065","article-title":"Influence of a Three-Dimensional, Microarray Environment on Human Cell Culture in Drug Screening Systems","volume":"33","author":"Meli","year":"2012","journal-title":"Biomaterials"},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Scalise, M., Marino, F., Salerno, L., Cianflone, E., Molinaro, C., Salerno, N., De Angelis, A., Viglietto, G., Urbanek, K., and Torella, D. (2021). From Spheroids to Organoids: The Next Generation of Model Systems of Human Cardiac Regeneration in a Dish. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413180"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s44272-024-00012-0","article-title":"Progress, Application and Challenges of Liver Organoids","volume":"3","author":"Sang","year":"2024","journal-title":"Clin. Cancer Bull."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1136\/gutjnl-2019-319256","article-title":"Liver Organoids: From Basic Research to Therapeutic Applications","volume":"68","author":"Prior","year":"2019","journal-title":"Gut"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10937404.2010.483176","article-title":"Toxicity Testing in the 21st Century: A Vision and a Strategy","volume":"13","author":"Krewski","year":"2010","journal-title":"J. Toxicol. Environ. Health Part. B"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.molmed.2020.01.008","article-title":"Assessing Toxicity with Human Cell-Based In Vitro Methods","volume":"26","author":"Zink","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/HEP.0000000000000343","article-title":"Human Liver Organoids: From Generation to Applications","volume":"79","author":"Afonso","year":"2024","journal-title":"Hepatology"},{"key":"ref_252","first-page":"1917","article-title":"Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science (1979)"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1002\/mco2.274","article-title":"Organoids: The Current Status and Biomedical Applications","volume":"4","author":"Yang","year":"2023","journal-title":"MedComm"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1247125","DOI":"10.1126\/science.1247125","article-title":"Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies","volume":"345","author":"Lancaster","year":"2014","journal-title":"Science"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1242\/dev.118570","article-title":"Modeling Mouse and Human Development Using Organoid Cultures","volume":"142","author":"Huch","year":"2015","journal-title":"Development"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2014.11.050","article-title":"Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver","volume":"160","author":"Huch","year":"2015","journal-title":"Cell"},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Tong, Y., Ueyama-Toba, Y., Yokota, J., Matsui, H., Kanai, M., and Mizuguchi, H. (2024). Efficient Hepatocyte Differentiation of Primary Human Hepatocyte-Derived Organoids Using Three Dimensional Nanofibers (HYDROX) and Their Possible Application in Hepatotoxicity Research. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-61544-y"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"105608","DOI":"10.1016\/j.phrs.2021.105608","article-title":"Liver Organoid as a 3D in Vitro Model for Drug Validation and Toxicity Assessment","volume":"169","author":"Brooks","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"100197","DOI":"10.1016\/j.crtox.2024.100197","article-title":"IPSC-Derived and Patient-Derived Organoids: Applications and Challenges in Scalability and Reproducibility as Pre-Clinical Models","volume":"7","author":"Heinzelmann","year":"2024","journal-title":"Curr. Res. Toxicol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced Pluripotent Stem Cells in Disease Modelling and Drug Discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Kim, H.-Y., Charton, C., Shim, J.H., Lim, S.Y., Kim, J., Lee, S., Ohn, J.H., Kim, B.K., and Heo, C.Y. (2024). Patient-Derived Organoids Recapitulate Pathological Intrinsic and Phenotypic Features of Fibrous Dysplasia. Cells, 13.","DOI":"10.3390\/cells13090729"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3892\/br.2017.867","article-title":"Pluripotent Stem Cells to Hepatocytes, the Journey so Far","volume":"6","author":"Palakkan","year":"2017","journal-title":"Biomed. Rep."},{"key":"ref_263","first-page":"3015","article-title":"Deconstructing the Third Dimension\u2014How 3D Culture Microenvironments Alter Cellular Cues","volume":"125","author":"Baker","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.stemcr.2019.08.007","article-title":"Robust, Long-Term Culture of Endoderm-Derived Hepatic Organoids for Disease Modeling","volume":"13","author":"Akbari","year":"2019","journal-title":"Stem Cell Rep."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00018-015-2092-y","article-title":"Molecular Specification of Germ Layers in Vertebrate Embryos","volume":"73","author":"Kiecker","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/term.2117","article-title":"Techniques for the Induction of Human Pluripotent Stem Cell Differentiation towards Cardiomyocytes","volume":"11","author":"Lewandowski","year":"2017","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"114790","DOI":"10.1016\/j.taap.2019.114790","article-title":"Development of Organoid-Based Drug Metabolism Model","volume":"385","author":"Park","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.tem.2024.07.019","article-title":"Patient-Derived Organoid Models to Decode Liver Pathophysiology","volume":"36","author":"Dwyer","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jhep.2019.06.030","article-title":"Generation of Expandable Human Pluripotent Stem Cell-Derived Hepatocyte-like Liver Organoids","volume":"71","author":"Mun","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"Luo, Q., Wang, N., Que, H., Mai, E., Hu, Y., Tan, R., Gu, J., and Gong, P. (2023). Pluripotent Stem Cell-Derived Hepatocyte-like Cells: Induction Methods and Applications. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411592"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","article-title":"High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell\u2013Derived Organoids","volume":"160","author":"Shinozawa","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"e1015","DOI":"10.1002\/cpz1.1015","article-title":"Prediction of Acute Hepatotoxicity With Human Pluripotent Stem Cell-Derived Hepatic Organoids","volume":"4","author":"Kim","year":"2024","journal-title":"Curr. Protoc."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Huang, Y., Huang, Z., Tang, Z., Chen, Y., Huang, M., Liu, H., Huang, W., Ye, Q., and Jia, B. (2021). Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.740574"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"30087","DOI":"10.1021\/acsomega.4c03683","article-title":"A Decade of Organoid Research: Progress and Challenges in the Field of Organoid Technology","volume":"9","author":"Ahammed","year":"2024","journal-title":"ACS Omega"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug-Drug-Gene Interactions and Adverse Drug Reactions","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenom. J."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.2010.03717.x","article-title":"Influences of Different Proton Pump Inhibitors on the Anti-platelet Function of Clopidogrel in Relation to CYP2C19 Genotypes","volume":"70","author":"Furuta","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation Is a Major Regulator of Drug Metabolizing Enzymes and Transporters: Consequences for the Personalization of Drug Treatment","volume":"215","author":"Chhun","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"71","DOI":"10.15171\/bi.2016.10","article-title":"Computerized Techniques Pave the Way for Drug-Drug Interaction Prediction and Interpretation","volume":"6","author":"Safdari","year":"2016","journal-title":"BioImpacts"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1109\/TCBB.2021.3081268","article-title":"A Comprehensive Review of Computational Methods For Drug-Drug Interaction Detection","volume":"19","author":"Qiu","year":"2022","journal-title":"IEEE ACM Trans. Comput. Biol. Bioinform."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2013.01.006","article-title":"Informatics Confronts Drug-Drug Interactions","volume":"34","author":"Percha","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1208\/s12248-008-9042-7","article-title":"In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and Their Utility for Predicting Drug-Drug Interactions","volume":"10","author":"Fowler","year":"2008","journal-title":"AAPS J."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/psp4.12605","article-title":"Comprehensive PBPK Model to Predict Drug Interaction Potential of Zanubrutinib as a Victim or Perpetrator","volume":"10","author":"Wang","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Lee, J.-M., Yoon, J.-H., Maeng, H.-J., and Kim, Y.C. (2024). Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict CYP3A-Mediated Drug Interaction between Saxagliptin and Nicardipine: Bridging Rat-to-Human Extrapolation. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020280"},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Zhu, J., Che, C., Jiang, H., Xu, J., Yin, J., and Zhong, Z. (2024). SSF-DDI: A Deep Learning Method Utilizing Drug Sequence and Substructure Features for Drug-Drug Interaction Prediction. BMC Bioinform., 25.","DOI":"10.1186\/s12859-024-05654-4"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1081\/DMR-120001391","article-title":"Structure\u2013Activity Relationship for Human Cytochrome P450 Substrates and Inhibitors","volume":"34","author":"Lewis","year":"2002","journal-title":"Drug Metab. Rev."},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Mei, S., and Zhang, K. (2021). A Machine Learning Framework for Predicting Drug-Drug Interactions. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-97193-8"},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Generaux, G.T. (2018). In Vitro Modeling of Drug-Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions, Springer International Publishing.","DOI":"10.1007\/978-3-319-72422-5_7"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-024-01457-1","article-title":"Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards","volume":"64","author":"Tiryannik","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u2018In Silico\u2019 Simulations to Assess the \u2018in Vivo\u2019 Consequences of \u2018in Vitro\u2019 Metabolic Drug-Drug Interactions","volume":"1","author":"Tucker","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17425255.2023.2263358","article-title":"Enhancing Drug-Drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4","volume":"19","author":"Jiang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s11095-022-03274-2","article-title":"Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective","volume":"39","author":"Lin","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Spanakis, M., Tzamali, E., Tzedakis, G., Koumpouzi, C., Pediaditis, M., Tsatsakis, A., and Sakkalis, V. (2025). Artificial Intelligence Models and Tools for the Assessment of Drug\u2013Herb Interactions. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030282"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/747\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:47:32Z","timestamp":1760032052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":292,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["pharmaceutics17060747"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17060747","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}